Tirzepatide dosage calculator: how the math actually works

Last updated 2026-07-27

What does a tirzepatide dosage calculator actually calculate?

A dosage calculator does one narrow job: it turns a prescribed dose in milligrams into a volume in milliliters (or units on an insulin-style syringe) that matches the concentration of the specific vial you have in hand. It does not decide what your dose should be. That decision belongs to the prescriber, and it follows the FDA-approved titration schedule for tirzepatide (brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management) ^[1][2]. Here's the actual math. If a vial is labeled 10 mg/mL and you're prescribed 2.5 mg, you need 0.25 mL. On a standard U-100 insulin syringe (where 100 units equals 1 mL), that's 25 units. Change the vial concentration and every number changes with it, which is exactly why calculator errors and manual math errors happen: people plug in the dose but use the wrong concentration, or they use a syringe marked in mL when they meant to read units, or vice versa. This matters more with compounded tirzepatide than with the pre-filled pens Eli Lilly manufactures. Zepbound and Mounjaro pens are pre-measured and click to a set dose. There's no math for the patient to do. Compounded tirzepatide, dispensed in multi-dose vials by a compounding pharmacy, requires the patient (or the calculator) to convert mg to mL correctly every single time, which is where a dosing calculator or a printed dosing chart from your provider earns its keep. For the reconstitution step that comes before any of this math, see how to reconstitute Tirz Rx.

What is the FDA-approved tirzepatide dosing schedule?

Tirzepatide starts at 2.5 mg subcutaneously once weekly for the first 4 weeks. This starting dose is not intended to produce meaningful glycemic control or weight loss; it exists to let the body adjust to the drug's GI effects before the dose increases ^[1][2]. After 4 weeks, the dose increases in 2.5 mg increments every 4 weeks, as tolerated, up to a maintenance dose. The FDA label for Zepbound lists five dose levels: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly, with 5 mg as the minimum effective (target) dose and 15 mg as the maximum ^[2]. Mounjaro's label for type 2 diabetes uses the same increments, with maintenance doses of 5 mg, 10 mg, or 15 mg once weekly ^[1]. Here is the schedule in table form, matching FDA prescribing information: | Weeks | Dose | Purpose |

How do you convert mg to mL and syringe units for tirzepatide?

The conversion depends entirely on the vial's labeled concentration, which varies by compounding pharmacy and by fill. There is no single universal answer, which is the exact reason calculators exist and the exact reason you should sanity-check them. The formula: mL needed = (prescribed dose in mg) divided by (vial concentration in mg/mL). Multiply the mL result by 100 to get insulin syringe units, since a standard U-100 syringe reads 100 units per 1 mL. Worked example: a vial reads 20 mg/mL. A prescribed dose of 5 mg means 5 divided by 20 equals 0.25 mL, or 25 units on a U-100 syringe. Change that same vial to 30 mg/mL and the same 5 mg dose becomes 0.167 mL, or roughly 17 units. This is why mixing up which vial you're drawing from, or misreading the label, is the single most common source of dosing errors reported to poison control centers and reflected in FDA adverse event data for compounded semaglutide and tirzepatide, which prompted an FDA consumer alert about dosing errors from vials and syringes with different measurement units ^[3]. Any calculator worth using asks for both numbers explicitly (your dose and your vial's concentration) and shows its work rather than just spitting out a units figure. If a tool doesn't show the intermediate mL step, don't trust it blindly; do the division yourself as a check. For the actual injection mechanics once you've drawn the correct volume, see Tirz Rx how to inject.

What did the SURMOUNT and SURPASS trials actually show about dose and outcome?

The dose-response relationship in tirzepatide's trials is one of the clearest in the obesity drug class, and it's worth knowing the actual numbers rather than a vague 'higher dose, more loss' claim. In SURMOUNT-1 (NCT04184622), adults with obesity or overweight plus a weight-related condition, without diabetes, lost a mean 15.0% of body weight on 5 mg weekly, 19.5% on 10 mg, and 20.9% on 15 mg at 72 weeks, compared with 3.1% on placebo ^[4]. All three active doses beat placebo by a wide margin, and the gap between 10 mg and 15 mg was smaller than the gap between 5 mg and 10 mg, a pattern typical of dose-response curves that are flattening near the top. SURPASS-2 (NCT03987919), which enrolled adults with type 2 diabetes and compared tirzepatide against semaglutide 1 mg, found A1C reductions of 2.01%, 2.24%, and 2.30% for tirzepatide 5 mg, 10 mg, and 15 mg respectively, versus 1.86% for semaglutide 1 mg, over 40 weeks ^[5]. Weight loss in the same trial ran from 7.6 kg at 5 mg to 11.2 kg at 15 mg, versus 5.7 kg on semaglutide ^[5]. The trial data shows a real clinical tradeoff: higher doses produce more weight loss and better glycemic control on average, but they also come with more GI side effects during titration, which is exactly why the FDA-approved schedule titrates slowly instead of starting at a therapeutic dose.

How does a compounded tirzepatide dosage calculator differ from a Zepbound pen dose?

Branded Zepbound and Mounjaro come in single-dose auto-injector pens pre-filled to an exact FDA-approved strength; there is no calculator involved because there's no math for the patient to do. You click the pen, it delivers the labeled dose, done ^[1][2]. Compounded tirzepatide is different by design. It is not FDA-approved, meaning no compounded tirzepatide product has gone through FDA's review of safety, efficacy, and manufacturing consistency the way Mounjaro and Zepbound have. It exists legally in a narrower channel: FDA permits compounding a drug on the FDA drug shortage list, or compounding for an individual patient's prescription needs under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, when the commercial product doesn't meet a specific patient's needs ^[6]. FDA removed tirzepatide from its drug shortage list in December 2024, which narrowed (though didn't eliminate) the legal basis compounders use to keep making it . Because compounded tirzepatide ships in multi-dose vials at pharmacy-specific concentrations, every dose requires a mg-to-mL conversion, and that's the entire reason a dosage calculator is a genuinely useful reference tool rather than a gimmick. A legitimate telehealth path pairs the compounded product with a provider who sets the titration schedule and a pharmacy that fills it accurately and labels the concentration clearly. Tirz Rx works through a provider-reviewed model, with orders filled by a licensed U.S. pharmacy partner, specifically so the mg-to-mL math is checked and printed for the patient rather than left to guesswork.

What is a safe way to double-check any calculator's result?

Never trust a single calculation, whether it comes from an app, a spreadsheet, or your own head, without a second check. The stakes are real: FDA has logged reports of patients hospitalized after dosing errors with compounded semaglutide and tirzepatide, largely from unit confusion between mL markings and unit markings on different syringe types ^[3]. Three checks worth running every time: First, confirm the vial's printed concentration (mg/mL) matches what you entered into the calculator, not what you remember from last time. Compounding pharmacies do change concentrations between fills. Second, do the division by hand: dose (mg) divided by concentration (mg/mL) equals mL. If the calculator's mL output doesn't match your own quick math, stop and call the pharmacy before drawing anything up. Third, know your syringe. A U-100 insulin syringe holds up to 100 units per mL and is marked in units, not mL, on most barrels. If your syringe is marked in mL instead of units, converting units back to mL (units divided by 100) is a second place for arithmetic slips to happen. Read the barrel markings before you fill, not after.

How often should the dose increase, and can you skip steps?

The label default is one step up every 4 weeks, not sooner ^[1][2]. Nothing in the SURMOUNT or SURPASS protocols supports jumping doses faster than that, and the trials themselves used the same 4-week titration cadence that's now on the FDA label ^[4][5]. A prescriber can also choose to hold a patient at a lower dose for longer than 4 weeks, which is common when GI side effects (nausea, diarrhea, constipation) are still settling down. There's no penalty for taking 8 or 12 weeks at 5 mg instead of 4, and for a meaningful share of patients that's the right call. Skipping straight to a higher dose, or restarting at a high dose after a gap in treatment, is where most serious GI reactions happen. If a dose is missed for more than a few weeks, restarting at the previous tolerated dose (not the last dose taken) is the safer approach, and that decision should go through the prescriber, not a calculator. For how gaps and restart timing interact with the drug's clearance, see Tirz Rx half life and Tirz Rx cycle length.

What side effects and warnings does the FDA label carry?

The tirzepatide label carries a boxed warning for thyroid C-cell tumors, based on findings in rodent studies; it's contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[1][2]. This isn't a minor footnote. It's the top warning on the label, and any provider prescribing tirzepatide should be asking about thyroid cancer family history before the first dose. The most common side effects in trials were gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain, most pronounced during dose increases and typically easing as the body adjusts ^[1][2]. In SURMOUNT-1, nausea occurred in about 24-33% of participants across the tirzepatide dose groups, versus about 10% on placebo, with rates rising somewhat at higher doses ^[4]. The label also warns about acute pancreatitis (a signal seen across the GLP-1/GIP class, though causality isn't fully established), gallbladder disease (including cholelithiasis and cholecystitis), acute kidney injury (often secondary to dehydration from GI side effects), hypoglycemia risk when combined with insulin or sulfonylureas, and diabetic retinopathy complications in patients with existing diabetic eye disease ^[1][2]. Anyone with a history of pancreatitis or gallbladder disease should flag it before starting.

Do injection site and technique affect the dose that's absorbed?

The FDA label lists the abdomen, thigh, and upper arm as approved subcutaneous injection sites, and clinical trials rotated among these sites without showing a meaningful difference in drug exposure by location ^[1][2]. Rotating sites week to week is still standard practice, mainly to reduce local irritation and lipohypertrophy risk rather than because one site absorbs the drug faster than another. What does affect the effective dose is technique: injecting into scar tissue, into a bruise, or too shallow (intradermal instead of subcutaneous) can change absorption unpredictably. None of that is calculator math, but it's just as relevant to whether the dose you drew up actually gets into your system as intended. For site rotation and technique specifics, see Tirz Rx injection sites.

Where does Tirz Rx fit into the calculator and dosing process?

Tirz Rx is not a pharmacy and does not compound, manufacture, or distribute tirzepatide. It's a provider-reviewed resource that connects patients researching tirzepatide with a licensed prescriber for evaluation and, if appropriate, a prescription filled by a fulfilling pharmacy partner. The dosage math described in this article, mg to mL to syringe units, is exactly the kind of detail a provider-reviewed process should hand you as a printed, pharmacy-confirmed chart rather than something you're left to calculate solo from a vial label at 11pm. If you're at the point of actually starting or adjusting treatment, the useful next step isn't a generic calculator widget; it's a conversation with a licensed prescriber who can confirm your vial's concentration, your titration step, and your syringe type together, and who reviews your thyroid and pancreatitis history against the boxed warning and contraindications before anything ships.

Frequently asked questions

How do I calculate tirzepatide dosage from mg to mL?

Divide your prescribed dose (mg) by the vial's labeled concentration (mg/mL). A 5 mg dose from a 20 mg/mL vial equals 0.25 mL. Multiply mL by 100 to get insulin syringe units (25 units in this example). Always confirm the vial's actual printed concentration first; it varies by pharmacy and by fill.

What is the standard tirzepatide starting dose?

FDA labeling for both Mounjaro and Zepbound starts patients at 2.5 mg subcutaneously once weekly for 4 weeks. This dose is a treatment-initiation step, not intended to produce meaningful glycemic control or weight loss, and it exists mainly to reduce GI side effects before the dose increases ^[1][2].

How much weight loss does each tirzepatide dose produce?

In SURMOUNT-1 at 72 weeks, mean weight loss was 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg weekly, versus 3.1% on placebo (NCT04184622) ^[4]. Individual results vary widely; these are trial averages, not guarantees, and results depend on diet, activity, and how long treatment continues.

Can I use an insulin syringe for tirzepatide?

Yes, a standard U-100 insulin syringe is commonly used for compounded tirzepatide dosing, since it's marked in units that correspond to 1/100 of a mL. The key risk is confusing unit markings with mL markings on different syringe types, which FDA has flagged as a real source of dosing errors ^[3].

How often does the tirzepatide dose increase?

The FDA-approved schedule increases the dose by 2.5 mg every 4 weeks, as tolerated, moving from 2.5 mg up through 5, 7.5, 10, 12.5, and 15 mg ^[1][2]. A prescriber can extend any step beyond 4 weeks if side effects haven't settled; there's no requirement to rush toward the maximum dose.

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No. Zepbound and Mounjaro are FDA-approved, made by Eli Lilly, and delivered in pre-filled pens with no patient math required. Compounded tirzepatide is not FDA-approved for safety, efficacy, or manufacturing consistency; it's produced under narrower FDA compounding rules and dispensed in vials that require mg-to-mL conversion ^[1][2][6].

What happens if I miscalculate my tirzepatide dose?

Overdosing raises the risk of severe GI side effects (nausea, vomiting, dehydration) and, per FDA reports, has led to hospitalizations from vial and syringe unit confusion ^[3]. Underdosing simply reduces effectiveness. If you suspect a dosing error, contact your prescriber or pharmacy immediately rather than adjusting the next dose yourself.

Does tirzepatide dose affect A1C reduction in type 2 diabetes?

Yes. SURPASS-2 (NCT03987919) found A1C reductions of 2.01% at 5 mg, 2.24% at 10 mg, and 2.30% at 15 mg over 40 weeks, all larger than the 1.86% reduction seen with semaglutide 1 mg in the same trial ^[5]. Higher tirzepatide doses produced modestly better glycemic control on average.

Who should not take tirzepatide regardless of dose?

Anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, should not take tirzepatide at any dose; this is a boxed warning contraindication on both the Mounjaro and Zepbound labels ^[1][2]. A history of pancreatitis or severe GI disease also warrants discussion with a prescriber first.

Can a dosage calculator replace a prescriber's titration plan?

No. A calculator only converts a prescribed mg dose into mL or units based on vial concentration; it can't set the dose, decide titration timing, or screen for contraindications like MTC/MEN2 history. That clinical judgment requires a licensed prescriber working from the FDA-approved titration schedule ^[1][2].

Why do different tirzepatide vials need different math?

Compounding pharmacies formulate vials at varying concentrations (commonly somewhere in the 10-30 mg/mL range depending on the pharmacy and fill), unlike Lilly's pre-filled pens which are fixed. That means the same prescribed mg dose can require a different mL volume depending on which vial you're using, so the concentration must be checked every time.

Is tirzepatide still on the FDA drug shortage list?

No. FDA removed tirzepatide products from its drug shortage list in December 2024, after determining supply had stabilized ^[7]. That removal narrowed, though did not fully eliminate, the legal basis some compounding pharmacies had relied on to produce large batches of compounded tirzepatide.

Sources

1. FDA, Mounjaro (tirzepatide) Prescribing Information: FDA-approved dosing schedule, titration steps, and boxed warning for Mounjaro
2. FDA, Zepbound (tirzepatide) Prescribing Information: FDA-approved dosing schedule, titration steps, and boxed warning for Zepbound
3. FDA, Medication Errors with Compounded Semaglutide and Tirzepatide: Dosing error reports linked to unit/mL confusion with compounded GLP-1 vials and syringes
4. NEJM, SURMOUNT-1 Trial (Jastreboff et al., 2022): Weight loss percentages by tirzepatide dose (5/10/15 mg) versus placebo at 72 weeks, NCT04184622
5. NEJM, SURPASS-2 Trial (Frias et al., 2021): A1C and weight change by tirzepatide dose versus semaglutide 1 mg, NCT03987919
6. FDA, Drug Shortages Database - Tirzepatide: FDA removed tirzepatide from the drug shortage list in December 2024